Early Phase 1 N=33 Mechanisms for Restoration of Hypoglycemia Awareness
Type1 Diabetes Mellitus
Primary: Brain Glucose Levels — 2.45; 2.16 Mmol/L — p=0.907
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=29 Naltrexone and Hypoglycemia in Type 1 Diabetes
Type 1 Diabetes · Hypoglycemia Unawareness
Primary: Cerebral Blood Flow — 1.7; 1.3 percentage of signal intensity change
N/A N=40 Impact on Hypoglycaemia Awareness of Real Time CGM and Intermittent Continuous Glucose Data
Type 1 Diabetes Mellitus With Hypoglycemia · Impaired Awareness of Hypoglycemia · Type1diabetes
Primary: % Time Spent in Hypoglycaemia (<3.3mmol/L, 60mg/dL) — -3.0; 1.3 percentage of time <3.3mmol/l — p=0.01
N/A N=10 Hybrid Closed Loop Insulin Delivery System in Hypoglycemia
Type1diabetes · Hypoglycemia Unawareness · Nocturnal Hypoglycemia
Primary: Endogenous Glucose Production — .66 [mg/(kgxmin)]
Phase 2 N=49 A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness
Type 1 Diabetes Mellitus With Hypoglycemia
Primary: Incidence of All AEs in Cohort 1 Participants — 33; 2; 24; 8 Adverse Events
N/A N=12 How Common is Hypoglycaemia in Older People With Diabetes Who Fall?
Diabetes · Hypoglycaemia
Primary: Proportion of Participants With Captured Hypoglycaemia — 3 Participants
N/A N=11 Hypoglycemia (Low Blood Sugar) and the Heart
Hypoglycemia · Type 2 Diabetes
Primary: Number of Participants With Hypoglycemia (Blood Sugar Level <70 mg/dl — 11 Participants
N/A N=37 Glucose Counterregulation in Long Standing Type 1 Diabetes
Hypoglycemia Unawareness · Type 1 Diabetes · Healthy
Primary: Endogenous Glucose Production — 0.54 mg/kg/min
N/A N=16 Cognition in Patients With Hypoglycemia, Without Diabetes
Hypoglycemia · Cognition
Primary: Assessment of Immediate Verbal Memory — 50; 48 RAVLT scores on a scale (range 0 to 69) — p=0.90
Early Phase 1 N=20 Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 4
Type 2 Diabetes
Primary: Percent Changes in Endothelial Function as Measured by Flow Mediated Dilation by 2D Doppler Ultrasound on Day 2 — 2; 7 percentage of change
N/A N=6 Testing Glial Pathways to HAAF in Human Subjects Using Carbon 13 Magnetic Resonance Spectroscopy
Diabetes Complications · Hypoglycemia
Primary: Percent Enrichment of Bicarbonate as Measured by Magnetic Resonance Spectroscopy (MRS) — 61.9 % enrichment — p=0.0053
N/A N=22 Hypoglycemia and Autonomic Nervous System Function
Hypoglycemia
Primary: Change in Baroreflex Sensitivity — 2.3; -1.6 ms/mmHg
N/A N=27 Effects of Mild Hypoglycaemia on Cognitive Function in Type 2 Diabetes
Diabetes Mellitus, Type II · Hypoglycemia · Cognitive Change
Primary: Psychomotor Speed — 48.7; 56.6 score on a scale
N/A N=35 Insulin Sensitivity, Impaired Counterregulation, and Glucose Variability
Type 1 Diabetes Mellitus
Primary: Insulin Sensitivity — 3.37*10^-4 1/min per uU/mL
N/A N=21 Hypoglycemia and the Mineralocorticoid Receptor
Hypoglycemia
Primary: Change From Baseline in Cardiovascular Autonomic Function — -16.00; -16.59 ms/mmHg
N/A N=587 Associated Factors in Perioperative Hypoglycemia in Patients With Diabetes
Diabetes · Hypoglycemia
Primary: Hypoglycemia Incidence — 53; 10 participants — p=<0.001
N/A N=41 Counter-Regulatory Impairment and the Effect of Microvascular Insulin Transfer in Type 1 Diabetes Mellitus
Diabetes Mellitus, Type 1
Primary: Maximum Epinephrine Response (LBGI Groups) — 495; 217 pg/ml
N/A N=1,069 The OBSTACLE Hypoglycemia Study (MK-0000-158)
Type 2 Diabetes
Primary: Correlation Between HbA1c Values at Week 12 and Hypoglycemia Scores — -0.1215 Correlation coefficient — p=0.0002
N/A N=40 Pilot Feasibility Study for HypoPals, a Mobile Health Program for Improving Hypoglycemia Management.
Type 1 Diabetes · Hypoglycemia
Primary: The Number of Participants Recruited to Reach 20 Participants That Complete the Intervention — 20 Participants
N/A N=259 Comparing the Effectiveness of Two Approaches to Preventing Severe Hypoglycemia in Patients With Type 2 Diabetes (PHT2)
Severe Hypoglycemia
Primary: Self-reported Severe Hypoglycemia — 99; 99; 19; 13 Participants — p=0.27
N/A N=14 Impact of Hypoglycaemia in Patients With Diabetes Mellitus Type 2 on Platelet Activation
Diabetes Mellitus With Hypoglycemia · Diabetes Mellitus, Type 2 · Hypoglycemia
Primary: Changes in Platelet Activation Marker Adenosin Diphosphate (%) — 63; 64.4; 64.4; 61.1 percentage of ADP
N/A N=22 Closed-Loop Glucagon Administration For Hypoglycemia Treatment
Type 1 Diabetes
Primary: Continuous Glucose Monitor (CGM) Glucose Total Area Over the Curve and Less Than 60 mg/dl — 1015; 4375.68 mg/dl/min
N/A N=10 Post Bariatric Closed Loop Glucagon Trial
Hypoglycemia
Primary: Area Over the Curve and <60 mg/dl (CGM) Measured in mg/dl *Min — 1066.30; 2004.80 mg/dl *minute
N/A N=719 Evaluation of Low Blood Sugar Events in Participants With Diabetes (MK-0431-402)
Type 2 Diabetes Mellitus
Primary: Number of Participants Experiencing Hypoglycemic Episodes in the 6 Months Prior to Enrollment — 305 Participants
N/A N=49 USS Virginia Closed-Loop Versus SAP Therapy for Hypoglycemia Reduction in T1D
Type 1 Diabetes Mellitus
Primary: Change in Hypoglycemia During Closed Loop Control (Assessed by Low Blood Glucose Index [LBGI]) — 2.51; 2.1; 1.28; 1.79 low blood glucose index — p=<0.001
Phase 2 N=16 The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Glycemic Response During Exercise and Early Recovery — 86; 85; 174; 161 mg/dL — p=<0.001
N/A N=16 Dipeptidyl Peptidase-4 Inhibitors and Alpha-cell Recovery
Type 1 Diabetes · Hypoglycemia
Primary: Glucagon Response to Acute Hypoglycaemia — 1.33; 1.0; 1.33 pmol/L — p=1.0
Phase 2 N=22 A Randomized Double Blinded Study to Examine the Use of N-acetyl Cysteine for the Prevention and Treatment of HAAF in Patients With Type 1 Diabetes
Type 1 Diabetes · Hypoglycemia Unawareness
Primary: Difference in Epinephrine Secretion During the Morning Episodes of Hypoglycemia on Days One and Two Under the Two Treatment Conditions — 622.8; 867 ug/ml
Phase 2 N=20 Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia
Diabetes Mellitus, Type 1
Primary: Number of Hypoglycemic Events ≥50 mg/dl 15 Minutes AND ≥ 70 mg/dl 30 Minutes After Initial Treatment — 58; 53 Hypoglycemic Events — p=0.99
Phase 3 N=129 Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
Hypoglycemia · Diabetes Mellitus · Drug-Specific Antibodies
Primary: Percentage of Participants Awakening or Returning to a Normal Status Within 30 Minutes Following Studied Drug of Administration — 95.7 percentage of participants